We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Juno (JUNO) Q2 Earnings: Will the Stock Disappoint?
Read MoreHide Full Article
Juno Therapeutics Inc. will be reporting second-quarter 2016 results on Aug 4, after the market closes. Juno, which started trading from Dec 2014, had delivered a negative earnings surprise of -17.91% in the last quarter. Let’s see how things are shaping up for this quarter.
Pipeline in Focus
With no approved products in its portfolio, Juno does not generate any product revenues. As a result, investor focus will be primarily on the company’s cash burn and pipeline updates.
Juno is looking to revolutionize cancer treatments by engaging the body’s immune system to treat cancer and is developing cell-based cancer immunotherapies based on CAR and high-affinity TCR technologies. This is a hot therapeutic area with huge commercial potential.
However, the company faced a major hiccup with the development of its lead pipeline candidate, JCAR015. Last month, the FDA had placed a clinical hold on the company’s phase II study (ROCKET) on JCAR015 in adult patients with relapsed or refractory B cell acute lymphoblastic leukemia (r/r ALL). The hold was placed after two patients died within a week due to severe neurotoxicity following the recent addition of fludarabine to the pre-conditioning regimen.
But the good news is that the clinical hold was lifted a week later and the study has resumed under a revised protocol.
We believe investor focus on the call will remain on updates regarding JCAR015, cash burn and revised timelines for filing for FDA approval of the candidate. Juno was previously looking to gain accelerated approval in the U.S. in 2017.
We note that at the time of releasing first-quarter results, Juno had said that it expects cash burn of $220 million - $250 million in 2016.
Juno has other interesting candidates in its pipeline as well as collaborations with companies like Celgene Corporation for the global development and commercialization of immunotherapies.
Surprise History
Juno has a mixed record with the company posting negative surprises in two quarters and in-line results in the other two quarters. The average earnings surprise over the last four quarters is -5.95%.
Our proven model does not conclusively show that Juno is likely to beat earnings estimates this quarter. This is because a stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) for this to happen. This is not the case here, as you will see below.
Zacks ESP: The Earnings ESP for Juno is -76.47%. This is because the Most Accurate estimate is a loss of 90 cents per share while the Zacks Consensus Estimate is a loss of 51 cents per share.
Zacks Rank: Juno carries a Zacks Rank #4 (Sell). Juno’s Zacks Rank #4 when combined with an ESP of -76.47% makes surprise prediction difficult.
We caution against stocks with a Zacks Rank #4 or 5 (Sell rated) going into the earnings announcement, especially when the company is seeing negative estimate revisions.
Stocks to Consider
Here are some health care stocks you may want to consider as our model shows that they have the right combination of elements to post a beat this quarter.
The Earnings ESP for Raptor Pharmaceuticals Corp. is +11.11% and it carries a Zacks Rank #3. The company will be reporting second-quarter results on Aug 4.
Bio-Techne Corp. (TECH - Free Report) has an Earnings ESP of +1.14% and carries a Zacks Rank #3. It is expected to report fourth-quarter fiscal 2016 results on Aug 4.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.Click to get this free report >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Juno (JUNO) Q2 Earnings: Will the Stock Disappoint?
Juno Therapeutics Inc. will be reporting second-quarter 2016 results on Aug 4, after the market closes. Juno, which started trading from Dec 2014, had delivered a negative earnings surprise of -17.91% in the last quarter. Let’s see how things are shaping up for this quarter.
Pipeline in Focus
With no approved products in its portfolio, Juno does not generate any product revenues. As a result, investor focus will be primarily on the company’s cash burn and pipeline updates.
Juno is looking to revolutionize cancer treatments by engaging the body’s immune system to treat cancer and is developing cell-based cancer immunotherapies based on CAR and high-affinity TCR technologies. This is a hot therapeutic area with huge commercial potential.
However, the company faced a major hiccup with the development of its lead pipeline candidate, JCAR015. Last month, the FDA had placed a clinical hold on the company’s phase II study (ROCKET) on JCAR015 in adult patients with relapsed or refractory B cell acute lymphoblastic leukemia (r/r ALL). The hold was placed after two patients died within a week due to severe neurotoxicity following the recent addition of fludarabine to the pre-conditioning regimen.
But the good news is that the clinical hold was lifted a week later and the study has resumed under a revised protocol.
We believe investor focus on the call will remain on updates regarding JCAR015, cash burn and revised timelines for filing for FDA approval of the candidate. Juno was previously looking to gain accelerated approval in the U.S. in 2017.
We note that at the time of releasing first-quarter results, Juno had said that it expects cash burn of $220 million - $250 million in 2016.
Juno has other interesting candidates in its pipeline as well as collaborations with companies like Celgene Corporation for the global development and commercialization of immunotherapies.
Surprise History
Juno has a mixed record with the company posting negative surprises in two quarters and in-line results in the other two quarters. The average earnings surprise over the last four quarters is -5.95%.
JUNO THERAPEUTC Price and EPS Surprise
JUNO THERAPEUTC Price and EPS Surprise | JUNO THERAPEUTC Quote
Earnings Whispers?
Our proven model does not conclusively show that Juno is likely to beat earnings estimates this quarter. This is because a stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) for this to happen. This is not the case here, as you will see below.
Zacks ESP: The Earnings ESP for Juno is -76.47%. This is because the Most Accurate estimate is a loss of 90 cents per share while the Zacks Consensus Estimate is a loss of 51 cents per share.
Zacks Rank: Juno carries a Zacks Rank #4 (Sell). Juno’s Zacks Rank #4 when combined with an ESP of -76.47% makes surprise prediction difficult.
We caution against stocks with a Zacks Rank #4 or 5 (Sell rated) going into the earnings announcement, especially when the company is seeing negative estimate revisions.
Stocks to Consider
Here are some health care stocks you may want to consider as our model shows that they have the right combination of elements to post a beat this quarter.
The Earnings ESP for Raptor Pharmaceuticals Corp. is +11.11% and it carries a Zacks Rank #3. The company will be reporting second-quarter results on Aug 4.
Bio-Techne Corp. (TECH - Free Report) has an Earnings ESP of +1.14% and carries a Zacks Rank #3. It is expected to report fourth-quarter fiscal 2016 results on Aug 4.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>